Memantine Hydrochloride Factory Supply High Purity Memantine HCl
|FOB Unit Price:||US $1 US $0.78|
|Purchase Qty. (g)||FOB Unit Price|
|Port:||Hong Kong, Hong Kong|
|Production Capacity:||200 Tons/Year|
|Payment Terms:||T/T, Western Union, Money Gram, Bitcoin|
- Model NO.: Memantine hydrochloride
- Customized: Customized
- Suitable for: Adult
- Purity: >99%
- Alias: Memantine HCl
- Einecs No: 255-219-6
- Molecular Weight: 215.76
- Trademark: YC
- Specification: USD Standard
- HS Code: 3001200010
- Powder: Yes
- Certification: GMP, HSE, ISO 9001
- State: Solid
- Product Name: Memantine Hydrochloride
- CAS Registry Number: 41100-52-1
- Molecular Formula: C12h22cln
- Appearance: White Powder
- Transport Package: 1 Kg/Foil Bag
- Origin: Hubei, China
Product name:Memantine hcl
Synonyms:Memantine hcl;Labotest-bb lt00233220;D-145;1,3-dimethyl-5-aminoadamantane hydrochloride;1,3-dimethylaminoadamantane hydrochloride;1-amino-3,5-dimethyladamantane hcl;1-amino-3,5-dimethyladamantane hydrochloride;1-amino-3,4-dimethyladamantane hydrochloride
Product categories:Adamantane derivatives;Antispasmodic;Antiparkinsonian;Adamantanes;Intermediates & fine chemicals;Pharmaceuticals;Glutamate receptor;Glutamate;Amines;Api;Other apis;Raw materials
Memantine hcl structure
Chemical properties crystalline solid
Usage used as an antiparkinsonian and antispasmodic
Usage antiparkinsonian;Dopaminergic agonist
Usage anti alzheimer's
Overview of memantine hydrochloride is dementia drugs developed by the german company merz, is a new type of low, moderate affinity, voltage dependent and non competitive n methyl d aspartate (nmda) receptor antagonist can noncompetitive nmda receptor blockade induced by glutamate receptor nmda, reduce the excessive excitement, prevent cell apoptosis, improve memory, is a new generation of drugs to improve cognitive function.
In february 2002, the european commission (cpmp) approved the drug patent for moderate to severe alzheimer's disease treatment, in august of the same year in the german market, in october 17, 2003 by the u.S.Food and drug administration (fda) approved for the treatment of moderate to severe alzheimer's disease patients.Further studies show that memantine hydrochloride is effective for mild to moderate alzheimer's disease.
Alzheimer's disease (alzheimer, disease, ad), also known as alzheimer's disease, is one of the common diseases of the elderly, mainly for the loss of memory and ability to identify barriers, is a progressive neurological degenerative disease.At present, cholinesterase inhibitors (donepezil, galantamine, kabbala ting) and memantine hydrochloride is approved for the treatment of blzheimer's disease.
Characters of memantine hydrochloride is white crystal or powder.Molecular weight:215.81.
Pharmacokinetics of oral administration of memantine hydrochloride has good absorption, and no food, treatment dose range, the linear dynamic feature of medicine, age and gender does not affect its pharmacokinetics.Oral administration of 3 ~ 7h peak blood concentration of t1/2 is 60 ~ 80h, the average volume of distribution of 9 ~ 11l / kg -1, the 45% rate of plasma protein binding, 57% ~ 82% to the rest of the prototype, metabolite of n -3, 5- two - methyl glucuronide, 6- hydroxy memantine and 1- nitroso - deamination dollars just by the form of urine excretion.Metabolites have a certain nmda receptor antagonist activity.Renal clearance was affected by urine ph, urine ph value was 8, renal clearance decreased by 80%.
Alzheimer's disease drugs